|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Selective Estrogen Receptor Modulators
La Merie Publishing, Jan 2010, Pages: 19
The present Competitive Intelligence Report about Selective Estrogen Receptor Modulators (SERM) provides a competitor evaluation in the field of small molecules selectively modulating estrogen receptor (SERM) as of January 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM. Effects on bone, endometrium and breast cancer are of interest. Tamoxifen is the widely investigated and most used representative of these drugs and has been introduced in treatment advanced breast cancer, in the neoadjuvant and adjuvant setting and for prevention of the disease. Other compounds are in development for breast cancer. The ongoing need for new osteoporosis therapies has led to the development of new selective estrogen receptor modulators (SERMs) with an ideal tissue selectivity profile and beneficial effects on bone without undesirable effects on the endometrium and breast.
The report includes a compilation of currently active projects in research and development of small molecules selectively modulating estrogen receptor (SERM). In addition, the report lists company-specific R&D pipelines of selective estrogen receptor modulators. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Oncology Pipeline Database
Drug Delivery in Cancer - Technologies, Markets and Companies
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Pain Therapeutics - Drugs, Markets and Companies
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
Triple Analysis: Breast Cancer, Cancer Vaccines and Protein Kinase Inhibitors
|
|
|
|
